Drug protein binding and the nephrotic syndrome.

abstract：:Sulphonylureas have remained the mainstay of oral therapy for type 2 (non-insulin-dependent) diabetes mellitus (NIDDM). They stimulate insulin release from pancreatic beta cells. Pharmacokinetic differences between the various sulphonylureas are of clinical importance in terms of the time to onset of action, timing of...

journal_title：Clinical pharmacokinetics

authors： Melander A,Donnelly R,Rydberg T

更新日期：1998-03-01 00:00:00

abstract：:A method is presented for the simultaneous estimation of functional hepatic blood flow and intrinsic clearance. The method uses pharmacokinetic data of a therapeutically employed drug and one of its primary metabolites following intravenous and oral administration of the parent compound. When the disposition of the dr...

journal_title：Clinical pharmacokinetics

authors： Weber W,Looby M,Brockmöller J

更新日期：1992-07-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Dosing of therapeutic monoclonal antibodies (mAbs) is often based on body size, with the perception that body size-based dosing would reduce inter-subject variability in drug exposure. However, most mAbs are target specific with a relatively large therapeutic window and generally a small contri...

journal_title：Clinical pharmacokinetics

authors： Bai S,Jorga K,Xin Y,Jin D,Zheng Y,Damico-Beyer LA,Gupta M,Tang M,Allison DE,Lu D,Zhang Y,Joshi A,Dresser MJ

更新日期：2012-02-01 00:00:00

abstract：:Hepatic and renal insufficiency due to co-infection, alcoholism, diabetes mellitus, family history, adverse effects of antiretrovirals and other factors are commonly seen in HIV-infected patients. Therefore, the use of antiretrovirals in this patient setting requires attention to the pharmacokinetic issues that clinic...

journal_title：Clinical pharmacokinetics

authors： McCabe SM,Ma Q,Slish JC,Catanzaro LM,Sheth N,DiCenzo R,Morse GD

更新日期：2008-01-01 00:00:00

abstract：:Rapid drug delivery (arterial "boli') and high drug concentrations occur with nicotine inhaled in smoke. These are believed to be key elements in producing addiction to cigarettes. Preparations which reduce the rate of delivery and/or concentration of nicotine have been introduced as treatments for smoking cessation. ...

journal_title：Clinical pharmacokinetics

authors： Schneider NG,Lunell E,Olmstead RE,Fagerström KO

更新日期：1996-07-01 00:00:00

abstract：:Since up to 90% of a theophylline dose is biotransformed, drugs influencing microsomal enzyme systems in the liver may affect the elimination of theophylline. Other integrated mechanisms (e.g. hepatic uptake) may also be altered by concurrent administration of other drugs. Whatever the mechanism, the interaction may b...

journal_title：Clinical pharmacokinetics

authors： Jonkman JH,Upton RA

更新日期：1984-07-01 00:00:00

abstract：OBJECTIVE:To determine the multiple dose pharmacokinetics of a new extended release (ER) capsule formulation of tolterodine, compared with the existing immediate release (IR) tablet, in healthy volunteers. DESIGN:Nonblind, randomised, 2-way crossover trial. PARTICIPANTS:19 healthy volunteers (7 females, 12 males), me...

journal_title：Clinical pharmacokinetics

authors： Olsson B,Szamosi J

更新日期：2001-01-01 00:00:00

abstract：:Nintedanib is an oral, small-molecule tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis and patients with advanced non-small cell cancer of adenocarcinoma tumour histology. Nintedanib competitively binds to the kinase domains of vascular endothelial growth factor (VEGF), platelet-de...

journal_title：Clinical pharmacokinetics

authors： Wind S,Schmid U,Freiwald M,Marzin K,Lotz R,Ebner T,Stopfer P,Dallinger C

更新日期：2019-09-01 00:00:00

abstract：:There are considerable laboratory data and information from animal and continuous culture in vitro models to support continuous infusion therapy for penicillins and cephalosporins, but, as yet, the only existing clinical data relate to cephalosporins. Penicillins do not exert concentration-dependent killing in the the...

journal_title：Clinical pharmacokinetics

authors： MacGowan AP,Bowker KE

更新日期：1998-11-01 00:00:00

abstract：:Protein binding of antibacterials in plasma and tissues has long been considered a component of their pharmacokinetic parameters, playing a potential role in distribution, excretion and therapeutic effectiveness. Since the beginning of the 'antibacterial era', this factor has been extensively analysed for all antibact...

journal_title：Clinical pharmacokinetics

authors： Bergogne-Bérézin E

更新日期：2002-01-01 00:00:00

abstract：:There is a considerable range in the dose of many drugs that is required to produce a given pharmacological effect in an individual patient. This individual variation in dose requirement is sometimes reflected in the wide scatter in the steady state plasma concentration that follows the same oral dose of a drug given ...

journal_title：Clinical pharmacokinetics

authors： Parsons RL

更新日期：1977-01-01 00:00:00

abstract：:The pharmacokinetics of CRP was tested in small short-term studies in both healthy volunteers and in subjects with schizophrenia, with similar results [242]. ...

journal_title：Clinical pharmacokinetics

authors： Mauri MC,Paletta S,Di Pace C,Reggiori A,Cirnigliaro G,Valli I,Altamura AC

更新日期：2019-09-01 00:00:00

abstract：OBJECTIVE:A prospective pharmacokinetic study was performed in Caucasian patients from an intensive care unit with respiratory support to evaluate the influence of this circumstance on the pharmacokinetic behaviour of levofloxacin. PATIENTS AND METHODS:A standard dosage regimen of 500 mg/day was administered to nine C...

journal_title：Clinical pharmacokinetics

authors： Sánchez Navarro A,Colino Gandarillas CI,Alvarez Lerma F,Menacho YA,Domínguez-Gil A

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Bayesian forecasting (BF) methods for tobramycin dose individualisation has not seen widespread clinical adoption, despite being endorsed by clinical practice guidelines. Several freeware and commercial programmes using BF methods are available to support personalised dosing. This study evalua...

journal_title：Clinical pharmacokinetics

authors： Burgard M,Sandaradura I,van Hal SJ,Stacey S,Hennig S

更新日期：2018-08-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Caspofungin is an echinocandin antifungal agent used as first-line therapy for the treatment of invasive candidiasis. The maintenance dose is adapted to body weight (BW) or liver function (Child-Pugh score B or C). We aimed to study the pharmacokinetics of caspofungin and assess pharmacokineti...

journal_title：Clinical pharmacokinetics

authors： Martial LC,Brüggemann RJ,Schouten JA,van Leeuwen HJ,van Zanten AR,de Lange DW,Muilwijk EW,Verweij PE,Burger DM,Aarnoutse RE,Pickkers P,Dorlo TP

更新日期：2016-06-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Milrinone is the drug of choice for the treatment and prevention of low cardiac output syndrome (LCOS) in paediatric patients after open heart surgery across Europe. Discrepancies, however, among prescribing guidance, clinical studies and practice pattern require clarification to ensure safe an...

journal_title：Clinical pharmacokinetics

authors： Vogt W

更新日期：2014-01-01 00:00:00

abstract：:Intraventricular administration of chemotherapy is one approach to overcoming the limited distribution of anticancer drugs and their active metabolites into the CNS. This form of regional chemotherapy has led to effective treatment of occult and overt meningeal leukaemia in humans. In contrast, the efficacy of this th...

journal_title：Clinical pharmacokinetics

authors： Fleischhack G,Jaehde U,Bode U

更新日期：2005-01-01 00:00:00

abstract：:Data on the pharmacokinetics of ofloxacin in chronic renal failure, in patients who were not dialysed or were receiving haemodialysis or continuous ambulatory peritoneal dialysis (CAPD), are reviewed. In addition, a large pool of data obtained in patients with a wide range of renal dysfunction is provided. The good ab...

journal_title：Clinical pharmacokinetics

authors： Lameire N,Rosenkranz B,Malerczyk V,Lehr KH,Veys N,Ringoir S

更新日期：1991-11-01 00:00:00

abstract：:The prevalence of HIV-associated neurocognitive disorder (HAND) is increasing despite the widespread use of combination antiretroviral therapy (ART). Initial reports suggest that the use of antiretrovirals with good central nervous system (CNS) penetration leads to better neurocognitive outcomes, but this has not yet ...

journal_title：Clinical pharmacokinetics

authors： Decloedt EH,Rosenkranz B,Maartens G,Joska J

更新日期：2015-06-01 00:00:00

abstract：:Uncertainty exists as to the most suitable pharmacokinetic parameter sets for propofol target-controlled infusions (TCI). The pharmacokinetic parameter sets currently employed are clearly not universally applicable, particularly when patient attributes differ from those of the subjects who participated in the original...

journal_title：Clinical pharmacokinetics

authors： Coetzee JF

更新日期：2012-03-01 00:00:00

abstract：:Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the 2,6-disubstituted naphthyl-alkanone class. Nabumetone is metabolised to an active metabolite 6-methoxy-2-napthylacetic acid (6-MNA) which is a relatively selective cyclo-oxygenase-2 inhibitor that has anti-inflammatory and analgesic properties. Nabumet...

journal_title：Clinical pharmacokinetics

authors： Davies NM

更新日期：1997-12-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Clearance is an important pharmacokinetic concept for scaling dosage, understanding the risks of drug-drug interactions and environmental risk assessment in children. Accurate clearance scaling to children requires prior knowledge of adult clearance mechanisms and the age-dependence of physiolo...

journal_title：Clinical pharmacokinetics

authors： Edginton AN,Schmitt W,Voith B,Willmann S

更新日期：2006-01-01 00:00:00

abstract：:Few of the articles published on antibiotics and pregnancy are concerned with pharmacokinetics. It is particularly difficult to evaluate possible alterations in pharmacokinetic parameters that may be due to pregnancy. Most data available have been obtained in connection with abortion or delivery. Such data may not be ...

journal_title：Clinical pharmacokinetics

authors： Philipson A

更新日期：1979-07-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Numerous population pharmacokinetic (PK) models of tacrolimus in adult transplant recipients have been published to characterize tacrolimus PK and facilitate dose individualization. This study aimed to (1) investigate clinical determinants influencing tacrolimus PK, and (2) identify areas requ...

journal_title：Clinical pharmacokinetics

authors： Kirubakaran R,Stocker SL,Hennig S,Day RO,Carland JE

更新日期：2020-11-01 00:00:00

abstract：:Carboplatin shares some of the therapeutic advantages of cisplatin, but without a significant incidence of the dose-limiting neurotoxicity and nephrotoxicity which is experienced with cisplatin. However, its use is associated with dose-limiting bone marrow suppression. Carboplatin is present in the blood as 3 distinct...

journal_title：Clinical pharmacokinetics

authors： Duffull SB,Robinson BA

更新日期：1997-09-01 00:00:00

abstract：BACKGROUND:Peripherally acting opioids, particularly peripheral κ-opioid agonists, may be effective for treating visceral pain by activating receptors expressed on afferent nerves within the gut. OBJECTIVE:The objective of this study was to investigate the pharmacokinetic/pharmacodynamic profile of a novel peripherall...

journal_title：Clinical pharmacokinetics

authors： Olesen AE,Kristensen K,Staahl C,Kell S,Wong GY,Arendt-Nielsen L,Drewes AM

更新日期：2013-02-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Understanding pharmacokinetic disposition of cefepime, a β-lactam antibiotic, is crucial for developing regimens to achieve optimal exposure and improved clinical outcomes. This study sought to develop and evaluate a unified population pharmacokinetic model in both pediatric and adult patients ...

journal_title：Clinical pharmacokinetics

authors： Liu J,Neely M,Lipman J,Sime F,Roberts JA,Kiel PJ,Avedissian SN,Rhodes NJ,Scheetz MH

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Vicriviroc is a small-molecule CCR5 antagonist currently in development for the treatment of HIV in patients on a regimen containing a ritonavir-boosted protease inhibitor. As renal disease and renal dysfunction are prevalent in the HIV-infected population, patients with varying degrees of rena...

journal_title：Clinical pharmacokinetics

authors： Kasserra C,Sansone-Parsons A,Keung A,Tetteh E,Assaf M,O'Mara E,Marbury T

更新日期：2010-06-01 00:00:00

abstract：:Voriconazole is both a substrate and a potent inhibitor of cytochrome P450 (CYP) 3A. It has a high bioavailability and non-linear pharmacokinetics. We investigated the pharmacokinetics and metabolism of 50 mg and 400 mg doses of intravenous and oral voriconazole in 14 healthy volunteers. Concurrently, we determined sy...

journal_title：Clinical pharmacokinetics

authors： Hohmann N,Kocheise F,Carls A,Burhenne J,Weiss J,Haefeli WE,Mikus G

更新日期：2016-12-01 00:00:00

abstract：:Short-term antimanic therapy with lithium and relapse-repressive, so-called "prophylactic" long-term therapy with lithium, may present clinical problems which demand an understanding of two cardinal properties of this form of therapy--the need to individualise the dose and the recognition that successful therapy invol...

journal_title：Clinical pharmacokinetics

authors： Amdisen A

更新日期：1977-03-01 00:00:00